Dr. Whittlesey is a scientist with more than 12 years of experiences facilitating the translation of regenerative medicine products. He earned his PhD in biological sciences from Northwestern University in neural tissue engineering for which he developed a novel biomaterials-mediated gene delivery technology and then conducted an NIH-funded postdoctoral fellowship at Aastrom Biosciences developing bone marrow derived stem cell-based products.
Dr. Whittlesey developed expertise in the public policy aspects of translational research through competitively awarded science and technology fellowships at the National Academy of Sciences and in the U.S. House of Representatives. He was then awarded an FDA Commissioner’s Fellowship for the regulation of regenerative medicine combination products, including serving as a product reviewer in the CBER Office of Cellular, Tissue, and Gene Therapies.
Dr. Whittlesey served as a Senior Science Officer at the California Institute for Regenerative Medicine (CIRM), the $3B state stem cell research funding agency. At CIRM he managed a $40 million portfolio of awards for translational biological products spanning preclinical IND-enabling research up through Phase 2 clinical trials.
At 4DMT, Dr. Whittlesey serves as the Project Leader for the Neuromuscular Diseases therapeutic area. He is responsible for all preclinical and IND-enabling activities for a portfolio of therapeutic candidates.